# A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

> **NCT01686555** · PHASE1 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 97 (actual)

## Conditions studied

- Lupus Erythematosus

## Interventions

- **DRUG:** ABT-199
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01686555
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2017-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01686555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01686555, "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01686555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*